Translational Development AcTDACU
13F holders, Q2 2026 (June 30)3holders −2
1new positions
3sold out
$11.31avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Translational Development Ac (TDACU) in their 13F filings, down 2 from Q1 2026. 1 opened new positions and 3 sold out. The largest holders were Clear Street Group Inc. ($140K), Flow Traders U.S. LLC ($132K) and UBS Group AG ($94K).
- Company
- Translational Development Ac
- CUSIP
- G9008W121
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $140K |
| Exits | 3 | $8.4M |
All 13F filers, Q1 2026 → Q2 2026: 12,344 shares bought and 787,429 shares sold, net −775,085 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Clear Street Group Inc. | 0.00% | New | 12,344 | $140K |
| Flow Traders U.S. LLC | 0.01% | Reduce -17.2% | 11,659 | $132K |
| UBS Group AG | 0.00% | Reduce -0.0% | 8,338 | $94K |
"% of holder's portfolio" is TDACU's weight in each manager's 13F, not the share of Translational Development Ac the manager owns.